---
title: 'Tumor immune evasion: insights from CRISPR screens and future directions'
date: '2023-11-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37971319/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231117170704&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Despite the clinical success of cancer immunotherapies including immune
  checkpoint blockade (ICB) and adoptive cellular therapies (ACTs) across a variety
  of cancer types, many patients do not respond or ultimately relapse, however, the
  molecular underpinnings of this are not fully understood. Thus, a systems level
  understating of the routes to tumor immune evasion is required to inform the design
  of the next generation of immunotherapy approaches. CRISPR screening approaches
  have ...
disable_comments: true
---
Despite the clinical success of cancer immunotherapies including immune checkpoint blockade (ICB) and adoptive cellular therapies (ACTs) across a variety of cancer types, many patients do not respond or ultimately relapse, however, the molecular underpinnings of this are not fully understood. Thus, a systems level understating of the routes to tumor immune evasion is required to inform the design of the next generation of immunotherapy approaches. CRISPR screening approaches have ...